Literature DB >> 7874389

Clinical comparison of adult and pediatric NeuroAIDS.

M Mintz1.   

Abstract

Human Immunodeficiency Virus type-1 (HIV-1)-associated neurologic disease occurs as the initial presenting clinical manifestation of acquired immunodeficiency syndrome (AIDS) in 3-7% of infected patients, but in up to 18% of children and adolescents (Janssen, 1992; Janssen et al., 1992; Scott et al., 1989; Mintz et al., 1989a; Epstein et al., 1986). The overall prevalence of dementia in adult AIDS patients is 7.3-11.3% (Janssen, 1992), but up to 30-60% of children with AIDS manifest an analogous progressive encephalopathy (Epstein et al., 1986; Belman et al., 1988; Mintz, 1992; The European Collaborative Study, 1990). As a result of both direct and indirect effects of HIV-1 infection of the central nervous system (CNS), a distinct clinical and pathologic picture has emerged of insidious and severe neurologic deterioration, termed "AIDS Dementia Complex" (ADC) in adults, and "HIV-1-associated Progressive Encephalopathy" (PE) in children (Working Group, 1991) (see Table 1). In the severe manifestations of this pariah, there is little dispute as to the necessity of CNS HIV-1 infection for precipitating the cascade of adverse neurologic symptoms, although the pathogenic mechanisms of neurologic dysfunction and destruction--whether a result of direct cellular infection of HIV, secondarily produced and upregulated cytotoxic cytokines, or co-infection with opportunistic pathogens--remains an area of active research (Epstein and Gendelman, 1993; Fiala et al., 1993; Wiley and Nelson, 1988; Saito et al., 1994; Koenig et al., 1986; Sharer, 1992). Furthermore, the existence of systemic immune deficiency renders the CNS susceptible to opportunistic infection (OI), particularly in adult patients, adding further to morbidity and mortality (Clifford and Campbell, 1992). With the introduction of antiretroviral nucleoside analogues, there have been reports of a decreasing incidence of ADC (Portegies et al., 1989; Day et al., 1992), and amelioration--at least temporarily--of PE in children (Pizzo et al., 1988; Mintz and Epstein, 1992; Brouwers et al., 1990; Mintz et al., 1990). This appends further evidence to the central precipitating role of CNS HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7874389     DOI: 10.1016/s0960-5428(06)80259-7

Source DB:  PubMed          Journal:  Adv Neuroimmunol        ISSN: 0960-5428


  21 in total

1.  Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder.

Authors:  Nimisha Gandhi; Zainulabedin M Saiyed; Jessica Napuri; Thangavel Samikkannu; Pichili V B Reddy; Marisela Agudelo; Pradnya Khatavkar; Shailendra K Saxena; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2010-07       Impact factor: 2.643

Review 2.  Vertical human immunodeficiency virus-1 infection: involvement of the central nervous system and treatment.

Authors:  C Exhenry; D Nadal
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

3.  Cognitive and motor deficits associated with HIV-2(287) infection in infant pigtailed macaques: a nonhuman primate model of pediatric neuro-AIDS.

Authors:  J M Worlein; J Leigh; K Larsen; L Kinman; A Schmidt; H Ochs; R J Y Ho
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

Review 4.  T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.

Authors:  Muhammad Mukhtar; Edward Acheampong; Zahida Parveen; Roger J Pomerantz
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 5.  Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.

Authors:  Shringika Soni; Rakesh Kumar Ruhela; Bikash Medhi
Journal:  Adv Pharm Bull       Date:  2016-09-25

6.  HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children.

Authors:  Carmen Cantó-Nogués; Silvia Sánchez-Ramón; Susana Alvarez; César Lacruz; Ma Angeles Muñóz-Fernández
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

7.  Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measures.

Authors:  Sylvia Fitting; Rosemarie M Booze; Charles F Mactutus
Journal:  Brain Res       Date:  2008-07-17       Impact factor: 3.252

8.  Human microglial cell isolation from adult autopsy brain: brain pH, regional variation, and infection with human immunodeficiency virus type 1.

Authors:  Kimberly Schuenke; Benjamin B Gelman
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

9.  Differential long-term neurotoxicity of HIV-1 proteins in the rat hippocampal formation: a design-based stereological study.

Authors:  Sylvia Fitting; Rosemarie M Booze; Ulla Hasselrot; Charles F Mactutus
Journal:  Hippocampus       Date:  2008       Impact factor: 3.899

10.  Dose-dependent long-term effects of Tat in the rat hippocampal formation: a design-based stereological study.

Authors:  Sylvia Fitting; Rosemarie M Booze; Ulla Hasselrot; Charles F Mactutus
Journal:  Hippocampus       Date:  2010-04       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.